Key Takeaway: Firefly Neuroscience has successfully listed on Nasdaq following a $45 million reverse merger with WaveDancer. The newly combined entity will focus on commercializing its FDA-cleared Brain Network Analytics platform. This platform aims to assist neurologists in the US and collaborate with pharmaceutical companies for developing treatments for central nervous system disorders.
Price reaction · baseline $7.8 (2024-08-14T14:01:00.000Z) · hit during market hours · 1 other AIFF headline(s) in the window, move may be shared
day 0 close
-18.6%
day 1 · peak
-21.8%
day 3
-19.1%
Market Sentiment Analysis
POSITIVE FACTORS
Successful listing on Nasdaq opens new financing opportunities.
Firefly's platform is FDA-cleared, enhancing credibility.
Partnerships with pharma companies could lead to innovative treatments.
Full Press Release Details
Canada’s Firefly Neuroscience has completed a listing on the Nasdaq via a $45 million reverse merger with IT group WaveDancer, opening up new financing routes for its artificial intelligence-powered platform for measuring brain function.
The combined company will operate under the Firefly Neuroscience banner and focus its efforts on commercialising the company’s FDA-cleared Brain Network Analytics (BNA) platform to neurologists in the US, and partner with pharma companies to use it for the development of new treatments for central nervous system disorders.
Read Article
Frequently Asked Questions
What is Firefly Neuroscience's recent achievement?
Firefly Neuroscience has listed on Nasdaq after a $45 million reverse merger.
What platform does Firefly Neuroscience focus on?
The company focuses on its FDA-cleared Brain Network Analytics platform.
Who will Firefly partner with for its platform?
Firefly plans to partner with pharmaceutical companies for treatment development.
What is the purpose of the Brain Network Analytics platform?
It is designed to measure brain function and assist neurologists.